Olmesartan

BreastfeedingPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

ACE inhibitors, Adrenergic neurone blockers, Aldesleukin, Aliskiren, Alprostadil, Amifostine, Antihypertensives, Antipsychotics, Anxiolytics and hypnotics, Baclofen, Beta blockers, Calcium channel blockers, Clonidine, Colesevelam, Corticosteroids, Cyclosporine, Diazoxide, Diuretics, Eltrombopag, Eplerenone, Estrogens, General anesthetics, Heparins, Hydralazine, Levodopa, Lithium, MAO inhibitors, Methyldopa, Methylphenidate, Minoxidil, Moxisylyte, Moxonidine, Nitrates, Nitroprusside, NSAIDs, Pentoxifylline, Phosphodiesterase 5 inhibitors, Potassium salts, Quinine, Rituximab, Tacrolimus, Tizanidine, Tolvaptan, Trimethoprim

PREGNANCY CATEGORY: D
category C in first trimester; category D in second and third trimesters

Contra-indicated in patients with diabetes.

FETAL TOXICITY

See full prescribing information for complete boxed warning.

Our database has 69 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
OTIC.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 06/20/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top